Key Takeaway: Enveric Biosciences has announced new preclinical data confirming that its lead drug candidate, EB-003, maintains a non-hallucinogenic profile. This finding supports the company's goal of treating psychiatric and neurological disorders while preserving neuroplasticity benefits without inducing hallucinations. The results are promising for future therapeutic applications.
Price reaction · baseline $1.54 (2026-08-05T13:33:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close · peak
+8.4%
day 1
+1.3%
day 3
0%
Market Sentiment Analysis
POSITIVE FACTORS
Reinforcement of non-hallucinogenic profile for EB-003.
Potential to treat psychiatric and neurological disorders.
Preserves therapeutic benefits of neuroplasticity.
Full Press Release Details
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinforcing the non-hallucinogenic nature of its primary drug candidate, EB-003. The company aims to treat psychiatric and neurological disorders by preserving the therapeutic benefits of neuroplasticity without inducing a hallucinatory experience.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is Enveric Biosciences' lead drug candidate aimed at treating psychiatric disorders.
What does the new data confirm?
The new preclinical data confirms the non-hallucinogenic nature of EB-003.
What disorders does EB-003 target?
EB-003 targets psychiatric and neurological disorders.
How does EB-003 work?
EB-003 aims to preserve neuroplasticity benefits without inducing hallucinations.